Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Rosalind Advisors Inc.'s 7th Largest Position

Rosalind Advisors Inc. grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 27.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,128,700 shares of the biopharmaceutical company's stock after acquiring an additional 243,700 shares during the quarter. Ocular Therapeutix accounts for 4.8% of Rosalind Advisors Inc.'s portfolio, making the stock its 7th biggest holding. Rosalind Advisors Inc. owned approximately 0.72% of Ocular Therapeutix worth $9,639,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in Ocular Therapeutix by 146.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company's stock worth $9,661,000 after purchasing an additional 660,080 shares during the last quarter. Braidwell LP grew its stake in shares of Ocular Therapeutix by 36.3% in the 3rd quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company's stock worth $19,486,000 after buying an additional 596,000 shares in the last quarter. Polar Asset Management Partners Inc. bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth about $4,288,000. FMR LLC raised its position in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company's stock valued at $3,779,000 after buying an additional 428,335 shares in the last quarter. Finally, PFM Health Sciences LP bought a new position in shares of Ocular Therapeutix in the 3rd quarter valued at about $3,505,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the sale, the insider now directly owns 193,444 shares of the company's stock, valued at $1,510,797.64. The trade was a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,895 shares of company stock worth $283,772. Company insiders own 3.50% of the company's stock.

Ocular Therapeutix Trading Up 1.9 %

Shares of NASDAQ:OCUL traded up $0.14 on Wednesday, hitting $7.67. 1,854,165 shares of the company's stock were exchanged, compared to its average volume of 1,510,337. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -5.81 and a beta of 1.34. Ocular Therapeutix, Inc. has a 12 month low of $4.06 and a 12 month high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The business's 50 day simple moving average is $7.55 and its two-hundred day simple moving average is $8.77.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. Analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

OCUL has been the topic of several analyst reports. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 11th. They set a "buy" rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.38.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.